1. 1. AliAbadi, F. S. and Lees, P. 2000. Antibiotic treatment for animals: effect on bacterial population and dosage regimen optimisation. Int. J. Antimicrob. Agents 14: 307–313.
2. 2. Boothe, H. W., Jones, S. A., Wilkie, W. S., Boeckh, A., Stenstrom, K. K. and Boothe, D. M. 2005. Evaluation of the concentration of marbofloxacin in alveolar macrophages and pulmonary epithelial lining fluid after administration in dogs. Am. J. Vet. Res. 66: 1770–1774.
3. 3. De Baere, S., Goossens, J., Osselaere, A., Devreese, M., Vandenbroucke, V., De Backer, P. and Croubels, S. 2011. Quantitative determination of T-2 toxin, HT-2 toxin, deoxynivalenol and deepoxy-deoxynivalenol in animal body fluids using LC-MS/MS detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 879: 2403–2415.
4. 4. de Jong, A., Thomas, V., Simjee, S., Moyaert, H., El Garch, F., Maher, K., Morrissey, I., Butty, P., Klein, U., Marion, H., Rigaut, D. and Vallé, M. 2014. Antimicrobial susceptibility monitoring of respiratory tract pathogens isolated from diseased cattle and pigs across Europe: the VetPath study. Vet. Microbiol. 172: 202–215.
5. 5. Ding, H., Li, Y., Chen, Z., Rizwan-ul-Haq, M. and Zeng, Z. 2010. Plasma and tissue cage fluid pharmacokinetics of marbofloxacin after intravenous, intramuscular, and oral single-dose application in pigs. J. Vet. Pharmacol. Ther. 33: 507–510.